CN101336898A - Anticancer sustained-released formulation loaded with platinum compound and synergist thereof - Google Patents
Anticancer sustained-released formulation loaded with platinum compound and synergist thereof Download PDFInfo
- Publication number
- CN101336898A CN101336898A CNA2008103029858A CN200810302985A CN101336898A CN 101336898 A CN101336898 A CN 101336898A CN A2008103029858 A CNA2008103029858 A CN A2008103029858A CN 200810302985 A CN200810302985 A CN 200810302985A CN 101336898 A CN101336898 A CN 101336898A
- Authority
- CN
- China
- Prior art keywords
- platinum
- acid
- sustained
- copolymer
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A compound anticancer sustained-released injection comprises sustained-released microspheres and a solvent. The sustained-released microspheres comprise an anticancer effective ingredient and a sustained-released adjuvant, and the solvent is a common solvent or a special solvent containing a suspending agent. The suspending agent has a viscosity of 100-3,000cp (20-30 DEG C) and is selected from sodium carboxymethyl cellulose, etc.; the anticancer effective ingredient is a platinum drug and/or a platinum drug synergist selected from an anti-mitosis drug and/or an alkylating agent; and the sustained-released adjuvant is selected from ethylene-vinyl acetate copolymer, polifeprosan, difatty acid and sebacic acid copolymer, poly(erucic acid dimmer-sebacic acid) copolymer, poly(fumaric acid-sebacic acid) copolymer, etc. The sustained-released microspheres can also be made into a sustained-released implant, which can sustain effective drug concentration by intratumoral or peritumoral injection or placement, and can distinctly reduce the systemic toxic reaction of drug and selectively enhance the curative effect of non-operative treatments such as chemotherapy and radiotherapy.
Description
(1) technical field
The present invention relates to a kind of compound anti-cancer medicinal slow release agent of platiniferous class medicine, belong to technical field of pharmaceuticals.Particularly, the invention provides the anticancer medicine slow-release preparation containing of a kind of platiniferous class medicine and/or its synergist, be mainly slow releasing injection and sustained-release implant.
(2) background technology
Treatment for cancer still mainly comprises methods such as operation, radiotherapy and chemotherapy at present.Therefore wherein operative treatment not only can not be removed the oncocyte that is dispersed in, and often recurs or causes tumor cell to stimulate diffusion transfer because of operation; Radiotherapy and traditional chemotherapy are not had a selectivity, and be difficult to tumor by local and form effective drug level or therapeutic dose, weak effect, toxicity is big, improves the restriction that medicine or radiological dose are subjected to general toxic reaction again merely.Referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82).
The local placement of chemotherapeutics can overcome above defective preferably, not only can obviously improve the drug level of tumor by local, and can significantly reduce general toxic reaction.A large amount of internal and external tests have demonstrated the therapeutic effect to entity tumor, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82) and Kong Qingzhong etc. " place cisplatin in the tumor and cure the former carbuncle in the occipital region tumor of rat " " surgery tumor magazine " 64 phase 268-273 pages or leaves (1997) (Kong Q et al., JSurg Oncol.1997 Oct; 64:268-273).Also can be referring to Chinese patent (ZL00111093.4; ZL96115937.5; Application number 001111264,001111272) and U.S.'s patent of invention (patent No. 6,376,525B1; 5,651,986; 5,626,862).
Yet, entity tumor is made up of tumor cell and mesenchyma stroma of tumors, wherein the blood vessel in the mesenchyma stroma of tumors not only provides support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).Moreover, the blood vessel in the mesenchyma stroma of tumors often causes the enhancing of tumor cell to the toleration of cancer therapy drug to conventional chemotherapy medicine and insensitive, consequently treatment failure.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth "; referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; etal., Int J Cancer.2004; 111 (4): 484-93).
Therefore, develop a kind of effective cancer therapy drug or Therapeutic Method and just become a current important topic.The present invention provides a kind of new anticancer pharmaceutical composition just at the deficiencies in the prior art, can suppress growth of tumour cell effectively, and can strengthen the treatment tumor effect of other medicines, reduces recurrence.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of anticancer medicine slow-release preparation containing of platiniferous class medicine is provided, particularly, is the anticancer medicine slow-release preparation containing of a kind of platiniferous class medicine and/or its synergist, is mainly slow releasing injection and sustained-release implant.
Platinum-like compounds is mainly used in entity tumors such as treatment gastric cancer, breast carcinoma abroad as a kind of new cancer therapy drug.Yet tangible general toxicity has greatly limited the application of this medicine in application process.
The present invention finds that medicine that has and platinum-like compounds share its antitumaous effect is strengthened mutually, below the platinum-like compounds antitumaous effect will be increased mutually medicine be referred to as the platinum-like compounds synergist; In addition, the compositions of platinum-like compounds or platinum-like compounds and its synergist is made drug level that anticancer medicine slow-release preparation containing (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduces the drug level of medicine in blood circulation, is reduced the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The above unexpected main contents of the present invention of finding to constitute.
Anti-cancer medicine sustained-release injection of the present invention is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release microparticle, the one-tenth following by percentage by weight is grouped into:
Biological effective components 0.5-60%
Slow-release auxiliary material 41-99.9%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component is platinum medicine and/or its synergist, and the platinum medicine synergist is selected from anti-mitosis medicine and/or alkylating agent; Slow-release auxiliary material is selected from copolymer (PLGA), ethylene vinyl acetate copolymer (EVAc), polifeprosan, the FAD of polylactic acid (PLA), polyglycolic acid and hydroxyacetic acid: one of decanedioic acid (SA) copolymer, xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin and white tempera or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
Platinum-like compounds is selected from cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, ring platinum, oxaliplatin, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, iproplatin, rice platinum, pick up platinum, sebriplatin, spiroplatin, zeniplatin.With cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin or oxaliplatin serve as preferred.
Above-mentioned platinum-like compounds shared ratio in compositions is decided because of concrete condition, can be 0.1%-50%, is good with 1%-30%, and 5%-20% is best.
Anti-mitosis medicine will make tumor cell stop at the different links of cell cycle.Anti-mitosis medicine mainly is selected from cytochalasin, mitoclomine, mitoflaxone, mitoguazone, mitonafide, mitopodozide, mitoquidone, mitosper, mitotane, mitotenamine, mitozolomide, Flavone acetic acid, colchisal, colchicine, Demecolcine, B cytochalasin B, naphthols, alpha-Naphthol, betanaphthol, alpha-phosphate naphthols, acodazole, arsenicum, giracodazole and nocodazole.With colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole and nocodazole serves as preferred.
The percentage by weight of above-mentioned anti-mitosis medicine in slow releasing agent can be 0.01%-80%, is good with 1%-50%, and 5%-30% is best.
Above-mentioned alkylating agent is selected from alestramustine (Alestramustine); atrimustine (Atrimustine); ambamustine (Ambamustine); nimustine (ACNU; Nimustine); bendamustine (Bendamustine); ditiomustine (Ditiomustine); bofumustine (Bofumustine); carmustine (carmustine; BCNU; carmustine); elmustine (Elmustine); ecomustine (Ecomustine); galamustine (Galamustine; GCNU); fotemustine (Fotemustine); estramustine (Estramustine); hemustine heCNU He (hemustine; heCNU); pentamustine (Pentamustine; Neptamustine); mannomustine (Mannomustine; MCNU); lomustine (lomustine; CCNU; lomustine; chlorethyl cyclohexyl nitrosourea); methyl lomustine (methyl-CCNU); semustine (Semustine; CH3-CCNU; Me-CCNU); Ranimustine (Ranimustine); prednimustine (Prednimustine); uracil mustard (Uramustine; UracilMustard); Sarmustine SarCNU (SarCNU); tauromustine (Tauromustine); tallimustine (Tallimustine); spiromustine (Spiromustine); streptozocin (streptozotocin; STZ); the appropriate azoles amine of miaow (mitozolomide, MTZ); cyclophosphamide; melphalan; Chlorambucil; ifosfamide; 4H-peroxide cyclophosphamide; defosfamide; Mafosfamide; perfosfamide; hexamethylmelamine; cantharidin; norcantharidin; mannomustine; treosulfan; ritrosulfan; an improsulfan; etoglucid; pipobroman; piposulfan; triethylenemelaine; epoxypiperazine; benzene assistant TEPA; Phopurine; meturedepa; urethimine; a kind of or its combination in Ah bundle's TEPA.
The preferred nimustine of above-mentioned alkylating agent, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, Ah bundle's TEPA.
Above alkylating agent also comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate and maleate etc.
The percentage by weight of above-mentioned alkylating agent in slow releasing agent is good from 0.01%-99.99% with 1%-50%, is best with 5%-30%.
Anticancer effective component is mainly platinum medicine and/or its synergist.When the cancer therapy drug in the medicament slow-release microsphere only is platinum medicine or platinum medicine synergist, slow-releasing anticarcinogen injection is mainly used in the platinum medicine of other approach application of increase or the action effect of platinum medicine synergist, or is used for the potentiation to radiotherapy or other therapies.When the cancer therapy drug in the medicament slow-release microsphere only was platinum medicine or its synergist, the application of slow-releasing anticarcinogen injection and potentiation mode were:
(1) the platinum medicine synergist associating of the slow releasing injection of local injection platiniferous class medicine and other approach application;
(2) the platinum medicine associating of the slow releasing injection of local injection platiniferous class medicament synergistic agent and other approach application; Or
(3) associating of the slow releasing injection of the platiniferous class medicament synergistic agent of the slow releasing injection of local injection platiniferous class medicament synergistic agent and topical application.
The slow-releasing anticarcinogen injection of topical application also is used for the potentiation to radiotherapy or other therapies.Other approach refer to, but are not limited to tremulous pulse, vein, abdominal cavity, subcutaneous, intracavitary administration.
Percentage by weight in medicament slow-release microsphere is 0.5%-60%, is good with 2%-40%, is best with 5%-30%.The weight ratio of platinum medicine and platinum medicine synergist is 1-9: 1 to 1: 1-9, with 1-2: 1 serves as preferred.
Anticancer effective component percentage by weight in the anticancer slow-release microsphere of the present invention is preferably as follows:
(a) platinum in heptan, lobaplatin, nedaplatin or the oxaliplatin of 5-30%;
(b) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(c) nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine or Ah bundle's TEPA;
(d) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin or oxaliplatin and 5-30% the combination of colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(e) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, the nimustine of nedaplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA;
(f) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, the nimustine of giracodazole or nocodazole and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA; Or
(g) combination of the cyclophosphamide of appropriate azoles amine of the nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin or miaow and 5-30%, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, Ah bundle's TEPA.
One of the copolymer (PLGA) of the preferred polylactic acid of slow-release auxiliary material (PLA), polyglycolic acid and hydroxyacetic acid, ethylene vinyl acetate copolymer (EVAc), bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid) copolymer, poly-(fumaric acid-decanedioic acid) copolymer, polifeprosan or its combination.
When selecting the copolymer (PLGA) of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and mixture, glycolic and the hydroxy carboxylic acid of polyglycolic acid for use, PLA and PLGA content percentage by weight are respectively 0.1-99.9% and 99.9-0.1%.The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 30,000-50,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or decanedioic acid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, decanedioic acid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA)), bis-fatty acid-decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid-decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Except that above-mentioned adjuvant, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain anticancer component is suspended in gained in the injection, used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.
Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or.
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection is that biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer) is dissolved in some amphipathic solvent, adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or decanedioic acid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, decanedioic acid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).So viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, granule, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
The anticancer effective component and the percentage by weight of anti-cancer sustained-released implantation agent of the present invention are preferably as follows:
(a) ormaplatin of 5-30%, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, ring platinum, oxaliplatin, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, iproplatin, rice platinum, pick up platinum, sebriplatin, spiroplatin or zeniplatin;
(b) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(c) nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine or Ah bundle's TEPA;
(d) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, zeniplatin or oxaliplatin and 5-30% the combination of colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(e) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, the nimustine of zeniplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA;
(f) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, the nimustine of giracodazole or nocodazole and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA; Or
(g) combination of the cyclophosphamide of appropriate azoles amine of the nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin or miaow and 5-30%, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, Ah bundle's TEPA.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, is mainly slow releasing injection or sustained-release implant.Prepared tumor comprises various entity tumors.Comprise former of originating from brain and central nervous system or shift; And originate from the outer various entity tumors of cranium, as kidney, liver, gallbladder, incidence, the oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, the uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, former or cancer or sarcoma or the carcinosarcoma that shifts of rectum are wherein with the cerebral tumor, renal carcinoma, tumor of head and neck, thyroid carcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, cervical cancer, ovarian cancer, carcinoma of prostate, bladder cancer, colorectal former or metastatic carcinoma are preferred.
Route of administration depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.Can be in when operation or perioperatively tumor, tumor week injection or place; Can with radiation and systemic chemotherapy simultaneously or front and back separate applications, but sustained-release implant with in the tumor, tumor week inject or be placed as preferably.When the cancer therapy drug in the medicament slow-release microsphere only is platinum medicine or its synergist, the application of anti-cancer sustained-released implantation agent and the same slow releasing injection of potentiation mode.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technology of the present invention is further described:
The local drug concentration that test 1, different modes are used behind the cisplatin compares
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is treated behind tumor growth to 1 cm diameter it to be divided into following 8 groups (seeing Table 1) in its hypochondrium.Every group of dosage is 5mg/kg.Medicament contg (%) in the tumor when measuring the 3rd day.
Table 1
| Test group (n) | Administering mode | Medicament contg (%) in the 7th day tumor |
| 1(3) | The agent of abdominal cavity arteries and veins injection oxaliplatin normal injection | ＜1 |
| 2(3) | The agent of intratumor injection oxaliplatin normal injection | 8 |
| 3(3) | Tumor week injection oxaliplatin slow releasing injection | 58 |
| 4(3) | The agent of lumbar injection nedaplatin normal injection | ＜1 |
| 5(3) | Tumor week is placed the nedaplatin sustained-release implant | 78 |
| 6(3) | The agent of intratumor injection lobaplatin normal injection | 2 |
| 7(3) | Intratumor injection lobaplatin slow releasing injection | 70 |
| 8(3) | Place the lobaplatin sustained-release implant in the tumor | 74 |
Above result shows, the local drug concentration significant difference of platinum medicine after different modes is used.Topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.
The interior tumor-inhibiting action of body that test 2, different modes are used behind the lobaplatin compares
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is treated behind tumor growth to 0.5 cm diameter it to be divided into following 9 groups (seeing Table 2) in its hypochondrium.Every group of dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 20th day.
Table 2
| Test group (n) | Administering mode | Gross tumor volume (cm 3) | The P value |
| 1(6) | - | 50 | |
| 2(6) | The agent of lumbar injection oxaliplatin normal injection | 42 | 0.08 |
| 3(6) | The agent of intratumor injection oxaliplatin normal injection | 38 | 0.06 |
| 4(6) | Tumor week injection oxaliplatin slow releasing injection | 18 | 0.01 |
| 5(6) | The agent of lumbar injection nedaplatin normal injection | 42 | ＜0.05 |
| 6(6) | Tumor week is placed the nedaplatin sustained-release implant | 16 | ＜0.01 |
| 7(6) | The agent of intratumor injection lobaplatin normal injection | 44 | 0.04 |
| 8(6) | Intratumor injection lobaplatin slow releasing injection | 16 | ＜0.001 |
| 9(6) | Place the lobaplatin sustained-release implant in the tumor | 12 | ＜0.001 |
Above result shows, oxaliplatin, nedaplatin, the tumor-inhibiting action significant difference of lobaplatin after different modes is used, and topical can obviously improve its tumor-inhibiting action, and is wherein best with the effect of placing sustained-release implant in intratumor injection slow releasing injection and the tumor.Local sustained release is good effect not only, and toxic and side effects is also little.
Tumor-inhibiting action in the body of test 3, platiniferous class medicine and platinum medicine synergist (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 10th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 70±12 | |
| 2(6) | Platinum medicine | 50±5.0 | ＜0.05 |
| 3(6) | Procodazole | 48±2.0 | ＜0.01 |
| 4(6) | Arsenicum | 42±2.0 | ＜0.01 |
| 5(6) | Acodazole | 52±3.2 | ＜0.01 |
| 6(6) | B cytochalasin B | 42±3.0 | ＜0.01 |
| 7(6) | Platinum medicine+procodazole | 28±2.2 | ＜0.001 |
| 8(6) | Platinum medicine+arsenicum | 30±3.4 | ＜0.001 |
| 9(6) | Platinum medicine+acodazole | 30±3.4 | ＜0.001 |
| 10(6) | Platinum medicine+B cytochalasin B | 20±2.2 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for platinum medicine (cisplatin) and used platinum medicine synergist-anti-mitosis medicine (procodazole, arsenicum, acodazole, B cytochalasin B), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 4, platinum medicine and platinum medicine synergist (slow releasing injection)
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Platinum medicine and platinum medicine synergist are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and is shown in Table 4.
Table 4
| Oncocyte | Platinum medicine | Giracodazole | Arsenicum | Nocodazole | Platinum medicine+giracodazole | Platinum medicine+arsenicum | Platinum medicine+nocodazole |
| CNS | 50％ | 50％ | 62％ | 62％ | 90％ | 88％ | 92％ |
| C6 | 44％ | 62％ | 64％ | 64％ | 94％ | 84％ | 94％ |
| SA | 42％ | 60％ | 56％ | 62％ | 88％ | 92％ | 92％ |
| BC | 40％ | 64％ | 54％ | 64％ | 94％ | 84％ | 82％ |
| BA | 46％ | 60％ | 62％ | 60％ | 92％ | 92％ | 90％ |
| LH | 40％ | 52％ | 62％ | 58％ | 90％ | 88％ | 84％ |
| PAT | 50％ | 50％ | 64％ | 56％ | 92％ | 86％ | 90％ |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (carboplatin) and platinum medicine synergist-anti-mitosis medicine (procodazole, arsenicum, giracodazole, nocodazole), can show significant potentiation when use in conjunction.
Same potentiation also sees the combination of platinum in heptan, lobaplatin, nedaplatin, oxaliplatin, DNA-2114 or enloplatin and colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole, and potentiation is in 48-85% (P＜0.05).
The tumor-inhibiting action of test 5, platinum medicine and platinum medicine synergist (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual tumor cell of liver subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 5).First group is contrast, and the 2nd to 10 group is the treatment group, and sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 10th day.
Table 5
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 80±10 | |
| 2(6) | Cyclophosphamide | 50±5.3 | ＜0.05 |
| 3(6) | Platinum medicine | 48±2.3 | ＜0.01 |
| 4(6) | Cyclophosphamide+platinum medicine | 34±2.4 | ＜0.001 |
| 5(6) | Melphalan | 48±3.0 | ＜0.01 |
| 6(6) | Melphalan+platinum medicine | 32±3.0 | ＜0.001 |
| 7(6) | Chlorambucil | 38±3.8 | ＜0.01 |
| 8(6) | Chlorambucil+platinum medicine | 24±2.6 | ＜0.001 |
| 9(6) | Ifosfamide | 46±4.8 | ＜0.01 |
| 10(6) | Ifosfamide+platinum medicine | 16±2.2 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (platinum in heptan) and platinum medicine thing synergist-alkylating agent (cyclophosphamide, melphalan, Chlorambucil, ifosfamide), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 6, platinum medicine and platinum medicine synergist (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group (platinum medicine or platinum medicine synergist) and therapeutic alliance group (platinum medicine and platinum medicine synergist).Medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 6) of index with inhibition rate of tumor growth.
Table 6
| Test group (n) | Suffered treatment | Tumor control rate (%) | The P value |
| 1(6) | Contrast | - | |
| 2(6) | Platinum medicine | 42 | ＜0.05 |
| 3(6) | 4H-peroxide cyclophosphamide | 40 | ＜0.01 |
| 4(6) | Defosfamide | 36 | ＜0.01 |
| 5(6) | Mafosfamide | 44 | ＜0.01 |
| 6(6) | Perfosfamide | 46 | ＜0.01 |
| 7(6) | Platinum medicine+4H-peroxide cyclophosphamide | 84 | ＜0.001 |
| 8(6) | Platinum medicine+defosfamide | 82 | ＜0.001 |
| 9(6) | Platinum medicine+Mafosfamide | 72 | ＜0.001 |
| 10(6) | Platinum medicine+perfosfamide | 82 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (lobaplatin) and platinum medicine synergist-alkylating agent (4H-peroxide cyclophosphamide, defosfamide, Mafosfamide, perfosfamide), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 7, platinum medicine and platinum medicine synergist (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 7) of index with inhibition rate of tumor growth.
Table 7
| Test group (n) | Suffered treatment | Tumor control rate (%) | The P value |
| 1(6) | Contrast | - | |
| 2(6) | Platinum medicine | 56 | ＜0.05 |
| 3(6) | Hexamethylmelamine | 50 | ＜0.01 |
| 4(6) | Cantharidin | 46 | ＜0.01 |
| 5(6) | Norcantharidin | 46 | ＜0.01 |
| 6(6) | Mannomustine | 48 | ＜0.01 |
| 7(6) | Platinum medicine+hexamethylmelamine | 88 | ＜0.001 |
| 8(6) | Platinum medicine+cantharidin | 84 | ＜0.001 |
| 9(6) | Platinum medicine+norcantharidin | 90 | ＜0.001 |
| 10(6) | Platinum medicine+mannomustine | 92 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (nedaplatin) and platinum medicine synergist-alkylating agent (hexamethylmelamine, cantharidin, norcantharidin, mannomustine), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 8, platinum medicine and platinum medicine synergist (sustained-release implant)
With the rat is subjects, with 2 * 10
5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 8) of index with inhibition rate of tumor growth.
Table 8
| Test group (n) | Suffered treatment | Tumor control rate (%) | The P value |
| 1(6) | Contrast | - | |
| 2(6) | Platinum medicine | 58 | ＜0.05 |
| 3(6) | Treosulfan | 48 | ＜0.05 |
| 4(6) | Ritrosulfan | 46 | ＜0.05 |
| 5(6) | An improsulfan | 50 | ＜0.05 |
| 6(6) | Etoglucid | 52 | ＜0.01 |
| 7(6) | Platinum medicine+treosulfan | 86 | ＜0.01 |
| 8(6) | Platinum medicine+ritrosulfan | 86 | ＜0.01 |
| 9(6) | Platinum medicine+improsulfan | 78 | ＜0.01 |
| 10(6) | Platinum medicine+etoglucid | 88 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (oxaliplatin) and platinum medicine synergist-alkylating agent (treosulfan, ritrosulfan, an improsulfan, etoglucid), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 9, platinum medicine and platinum medicine synergist (sustained-release implant)
By the tumor-inhibiting action of test 8 described methods mensuration platinum medicines and platinum medicine synergist (sustained-release implant), its inhibition rate of tumor growth sees Table 9.
Table 9
| Test group (n) | Suffered treatment | Tumor control rate (%) | The P value |
| 1(6) | Contrast | - | |
| 2(6) | Platinum medicine | 58 | ＜0.05 |
| 3(6) | Triethylenemelaine | 44 | ＜0.01 |
| 4(6) | Epoxypiperazine | 50 | ＜0.01 |
| 5(6) | Urethimine | 44 | ＜0.01 |
| 6(6) | Ah bundle's TEPA | 46 | ＜0.01 |
| 7(6) | Platinum medicine+triethylenemelaine | 88 | ＜0.001 |
| 8(6) | Platinum medicine+epoxypiperazine | 80 | ＜0.001 |
| 9(6) | Platinum medicine+urethimine | 90 | ＜0.001 |
| 10(6) | Platinum medicine+Ah bundle's TEPA | 92 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used platinum medicine (cisplatin) and platinum medicine synergist-alkylating agent (triethylenemelaine, epoxypiperazine, urethimine, Ah bundle's TEPA), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 10, platinum medicine and platinum-like compounds synergist (slow releasing injection)
Measure the tumor-inhibiting action of platinum-like compounds synergist (slow releasing injection) by test 7 described methods, the result shows and is selected from cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, the platinum medicine of zeniplatin or oxaliplatin can significantly strengthen nimustine, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the tumor killing effect of Ah bundle's TEPA, potentiation is in 58-88% (P＜0.01).
The tumor-inhibiting action of test 11, platinum-like compounds synergist (sustained-release implant)
Measure the tumor-inhibiting action of platinum-like compounds synergist (sustained-release implant) by test 8 described methods, the result shows and is selected from nimustine, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, the alkylating agent of the appropriate azoles amine of streptozocin or miaow can significantly strengthen cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the tumor killing effect of Ah bundle's TEPA, potentiation is in 46-84% (P＜0.05).。
The tumor-inhibiting action of test 12, platinum-like compounds synergist (slow releasing injection)
Measure the tumor-inhibiting action of platinum-like compounds synergist (slow releasing injection) by test 7 described methods, the result shows and is selected from colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole can significantly strengthen nimustine, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the tumor killing effect of Ah bundle's TEPA, potentiation is in 40-80% (P＜0.05).
In a word, growth all had the obvious suppression effect to kinds of tumor cells when used platinum medicine and various platinum medicine synergist were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is the combination of platinum medicine and any one platinum medicine synergist.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
With 90,90 and 80mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer put into (first), (second) and (the third) three container respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, add 10mg platinum in heptan, 10mg colchicine, 10mg platinum in heptan and 10mg colchicine respectively, shake up again the back with spray drying method for preparation contain 10% heptan platinum, 10% colchicine and 10% heptan platinum and the injectable microsphere of 10% colchicine.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that contained anticancer effective component and percentage by weight thereof are:
(1) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, zeniplatin or oxaliplatin;
(2) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole; Or
(3) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, zeniplatin or oxaliplatin and 5-30% the combination of colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole.
Embodiment 3.
With 70mg molecular weight peak value 65000 polylactic acid (PLGA, 75: 25) put into (first), (second) and (the third) three container respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in three containers, add 30mg carboplatin, 30mg cyclophosphamide, 15mg carboplatin and 15mg cyclophosphamide respectively, shake up the back contains 30% carboplatin, 30% cyclophosphamide, 15% carboplatin and 15% cyclophosphamide with spray drying method for preparation injectable microsphere again.Dried microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained anticancer effective component and percentage by weight thereof are:
(1) nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine or Ah bundle's TEPA; Or
(2) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, the nimustine of the 5-30% of zeniplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, the combination of urethimine or Ah bundle's TEPA.
Embodiment 5.
(EVAc) puts into container with the 70mg ethylene vinyl acetate copolymer, after adding 100 milliliters of dichloromethane dissolving mixings, add 20 milligrams heptan platinum and 10 milligrams of acodazoles, shake up again the back with spray drying method for preparation contain 20% heptan platinum and the injectable microsphere of 10% acodazole.Then microsphere is suspended in the injection that contains the 5-15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that contained anticancer effective component is:
The ormaplatin of 10-20%, dexormaplatin, heptan platinum, lobaplatin, nedaplatin or oxaliplatin and 10-20% the combination of colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole.
Embodiment 7.
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg lobaplatin and 10mg melphalan, shake up the back contains 20% lobaplatin and 10% melphalan with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that contained anticancer effective component is:
The cisplatin of 10-20%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, the nimustine of nedaplatin or oxaliplatin and 10-20%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, the combination of urethimine or Ah bundle's TEPA.
Embodiment 9
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 15mg nedaplatin and 15mg nocodazole, shake up the back contains 15% nedaplatin and 15% with spray drying method for preparation nocodazole injectable microsphere again.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that contained anticancer effective component is:
15% cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin or oxaliplatin and 15% the combination of cytochalasin, acodazole, arsenicum, giracodazole or nocodazole.
Embodiment 11
70mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg Chlorambucil and 20mg oxaliplatin, shake up the back contains 10% Chlorambucil and 20% oxaliplatin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that contained anticancer effective component is:
The cisplatin of 10-20%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, the nimustine of nedaplatin or oxaliplatin and 10-20%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, the combination of urethimine or Ah bundle's TEPA.
Embodiment 13
With 70mg molecular weight peak value 45000 polylactic acid (PLGA, 50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg cisplatin and 20mg4H-peroxide cyclophosphamide, shake up the back contains 10% cisplatin and 20%4H-peroxide cyclophosphamide with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 15-25 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
The method step that is processed into sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component and percentage by weight are:
(a) ormaplatin of 5-30%, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, ring platinum, oxaliplatin, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, iproplatin, rice platinum, pick up platinum, sebriplatin, spiroplatin or zeniplatin;
(b) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(c) nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine or Ah bundle's TEPA;
(d) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, zeniplatin or oxaliplatin and 5-30% the combination of colchicine, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, giracodazole or nocodazole;
(e) cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, the nimustine of zeniplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA;
(f) colchicine of 5-30%, B cytochalasin B, alpha-Naphthol, betanaphthol, acodazole, arsenicum, the nimustine of giracodazole or nocodazole and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA; Or
(g) combination of the cyclophosphamide of appropriate azoles amine of the nimustine of 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin or miaow and 5-30%, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, Ah bundle's TEPA.
Embodiment 15
The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:
A) the molecular weight peak value is the polylactic acid (PLA) of 10000-30000,30000-60000,60000-100000 or 100000-150000;
B) the molecular weight peak value is the polyglycolic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 and the copolymer of hydroxyacetic acid (PLGA), and wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;
C) ethylene vinyl acetate copolymer (EVAc);
D) 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer (polifeprosan);
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 1-10, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.
Claims (7)
1. the slow-releasing anticarcinogen injection of loaded with platinum medicine and synergist thereof is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent;
Wherein,
Anticancer effective component is platinum medicine and platinum medicine synergist;
Described platinum medicine is selected from cisplatin, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, ring platinum, oxaliplatin, DNA-2114, cis-Dichlorobis(cyclopentylamine)platinum, platinum blue, cis-Dichlorobis(cyclopropylamine)platinum, Ethylenediammineplatinum(II) malonate, CL 286558., enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, iproplatin, rice platinum, pick up platinum, sebriplatin, spiroplatin, zeniplatin;
Described platinum medicine synergist is an alkylating agent, is selected from alestramustine, atrimustine, ambamustine, nimustine, bendamustine, ditiomustine, bofumustine, carmustine, elmustine, ecomustine, galamustine, fotemustine, estramustine, hemustine heCNU He, pentamustine, mannomustine, lomustine, methyl lomustine, semustine, Ranimustine, prednimustine, uracil mustard, Sarmustine SarCNU, tauromustine, tallimustine, spiromustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, defosfamide, Mafosfamide, perfosfamide, hexamethylmelamine, cantharidin, norcantharidin, mannomustine, treosulfan, ritrosulfan, an improsulfan, etoglucid, pipobroman, piposulfan, triethylenemelaine, epoxypiperazine, benzene assistant TEPA, Phopurine, meturedepa, urethimine, one of Ah bundle's TEPA or its combination;
The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), is selected from one of sodium carboxymethyl cellulose, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
2. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that the anticancer effective component of slow-releasing anticarcinogen injection is:
The cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, the nimustine of nedaplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA;
Below all be weight percentage.
3. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that slow-release auxiliary material is selected from one of following or its combination:
A) polylactic acid;
B) copolymer of polyglycolic acid and hydroxyacetic acid;
C) polifeprosan;
D) ethylene vinyl acetate copolymer;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
4. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that used suspending agent is respectively one of following:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20;
F) (iodine) glycerol, simethicone, propylene glycol or carbomer;
G) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80;
H) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
I) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
5. be used to prepare the sustained-release implant that treatment originates from people and animal entity tumor according to the described anticancer slow-release microsphere of claim 1.
6. the anti-cancer sustained-released implantation agent according to claim 5 is characterized in that anticancer effective component and percentage by weight are:
The cisplatin of 5-30%, carboplatin, ormaplatin, dexormaplatin, heptan platinum, lobaplatin, nedaplatin, DNA-2114, enloplatin, iproplatin, spiroplatin, the nimustine of zeniplatin or oxaliplatin and 5-30%, carmustine, bendamustine, galamustine, Ranimustine, fotemustine, estramustine, Sarmustine SarCNU, semustine, lomustine, methyl lomustine, streptozocin, the appropriate azoles amine of miaow, cyclophosphamide, melphalan, Chlorambucil, ifosfamide, 4H-peroxide cyclophosphamide, etoglucid, benzene assistant TEPA, Phopurine, meturedepa, urethimine, the combination of Ah bundle's TEPA;
Slow-release auxiliary material is selected from one of following or its combination:
A) polylactic acid;
B) copolymer of polyglycolic acid and hydroxyacetic acid;
C) polifeprosan;
D) ethylene vinyl acetate copolymer;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) xylitol, oligosaccharide, chrondroitin, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or white tempera.
7. the described anti-cancer sustained-released implantation agent according to claim 5 is characterized in that entity tumor comprises to come from people and animal origin in former or cancer, sarcoma or the carcinosarcoma of secondary of people and animal kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103029858A CN101336898A (en) | 2006-02-20 | 2006-02-20 | Anticancer sustained-released formulation loaded with platinum compound and synergist thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103029858A CN101336898A (en) | 2006-02-20 | 2006-02-20 | Anticancer sustained-released formulation loaded with platinum compound and synergist thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006102001413A Division CN1850042A (en) | 2006-02-20 | 2006-02-20 | Anti-cancer slow-release preparation containing platinum medicines and its synergist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101336898A true CN101336898A (en) | 2009-01-07 |
Family
ID=40211167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008103029858A Pending CN101336898A (en) | 2006-02-20 | 2006-02-20 | Anticancer sustained-released formulation loaded with platinum compound and synergist thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101336898A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3373907A4 (en) * | 2015-11-11 | 2019-12-18 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
-
2006
- 2006-02-20 CN CNA2008103029858A patent/CN101336898A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3373907A4 (en) * | 2015-11-11 | 2019-12-18 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101433520A (en) | Anticancer sustained-release agent containing epothilone | |
| CN1969816A (en) | Anticancer sustained release agent containing epothilone | |
| CN100464736C (en) | Slow released anticancer injection with both antimetabolite and its synergist | |
| CN101336899A (en) | Anticancer sustained-released injection containing taxane | |
| CN101380303A (en) | Anti-cancer medicine sustained-released injection loaded with platinum compound and synergist thereof | |
| CN1969825A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
| CN100500215C (en) | Slow-released injection containing methotrexate and its synergist | |
| CN101336898A (en) | Anticancer sustained-released formulation loaded with platinum compound and synergist thereof | |
| CN1969824A (en) | Anticancer sustained release agent containing fluorouracil and synergist thereof | |
| CN100569289C (en) | The anticancer pharmaceutical composition of loaded with platinum compound and clofarabine | |
| CN1969823A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
| CN101011345A (en) | Slow release injection containing platinum compound and alkylating agent | |
| CN101427994B (en) | Gemcitabine-containing anti-cancer medicine sustained-release injection | |
| CN101006981A (en) | Slow released injection containing taxane and platinum | |
| CN100531715C (en) | Slow-released methotrexate injection | |
| CN1957920B (en) | Anti cancer slow release agent carrying fluorouracil and synergist | |
| CN101336900A (en) | Anticancer sustained-released injection containing taxane | |
| CN1969826A (en) | Fluorouracil and its synergist carried sustained release agent | |
| CN1875936B (en) | Anticancer sustained release agent containing clorfarabine and cytotoxic drug | |
| CN100531718C (en) | Slow-released injection containing methotrexate synergist | |
| CN101297970A (en) | Antimetabolites and potentiating agent thereof carried by anticancer sustained-release injection | |
| CN101011343A (en) | Slow release injection containing anti-metabolism medicament and alkylating agent | |
| CN101011342A (en) | Slow release injection containing anti-metabolism medicament and platinum compound | |
| CN101269008A (en) | Novel anticancer sustained-release agent | |
| CN101292956A (en) | Sustained-release injection containing methotrexate and its synergistic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090107 |